On May 17, 2006, a company that only experts in the health sector had heard of, Grifols, went public with a market value of 940 million euros.
Almost 15 years after that date,
Grifols is worth 13,000 million euros
and has become one of the stars of the Ibex 35. All in all, the current figure for one of the world leaders in blood products represents a fall of close to 30% compared to the maximum valuation of 19,000 million reached before the pan
Become Premium and
enjoy 3 months for € 1
Take advantage of this limited time offer and access all web content
I love you
Are you already Premium?
Log in
Cancel whenever you want
Check the terms and conditions of the service
According to the criteria of The Trust Project
Know more